Cargando…

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies

The aim of this study was to evaluate oxidative stress parameters, specifically the concentration of advanced oxidation protein products (AOPP) and ferric-reducing antioxidant power (FRAP), in the serum of patients with relapsing-remitting multiple sclerosis (RRMS). We also analyzed the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizoń, Anna, Chojdak-Łukasiewicz, Justyna, Kołtuniuk, Aleksandra, Budrewicz, Sławomir, Pokryszko-Dragan, Anna, Piwowar, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774652/
https://www.ncbi.nlm.nih.gov/pubmed/36552624
http://dx.doi.org/10.3390/antiox11122416
_version_ 1784855461973983232
author Bizoń, Anna
Chojdak-Łukasiewicz, Justyna
Kołtuniuk, Aleksandra
Budrewicz, Sławomir
Pokryszko-Dragan, Anna
Piwowar, Agnieszka
author_facet Bizoń, Anna
Chojdak-Łukasiewicz, Justyna
Kołtuniuk, Aleksandra
Budrewicz, Sławomir
Pokryszko-Dragan, Anna
Piwowar, Agnieszka
author_sort Bizoń, Anna
collection PubMed
description The aim of this study was to evaluate oxidative stress parameters, specifically the concentration of advanced oxidation protein products (AOPP) and ferric-reducing antioxidant power (FRAP), in the serum of patients with relapsing-remitting multiple sclerosis (RRMS). We also analyzed the relationships between each parameter and selected clinical/laboratory multiple-sclerosis-related parameters. The study group comprised 204 patients with RRMS and 29 healthy, age-matched controls. The concentration of AOPP was significantly higher in the RRMS patients than in controls. ROC analysis showed the ability of AOPP to distinguish between the patients with RRMS and controls (the value of AUC was 94.8%, with a sensitivity of 89.69% and specificity of 89.3%). AOPP and FRAP were significantly higher in male than in female RRMS patients. Correlations were found between AOPP and the laboratory markers of inflammation. AOPP differed in the subgroups of patients treated with particular medications. Our findings indicate an increase in the markers of oxidative stress in the serum of RRMS patients, possibly linked with chronic inflammation. Gender and type of treatment affected the markers of oxidative stress.
format Online
Article
Text
id pubmed-9774652
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97746522022-12-23 Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies Bizoń, Anna Chojdak-Łukasiewicz, Justyna Kołtuniuk, Aleksandra Budrewicz, Sławomir Pokryszko-Dragan, Anna Piwowar, Agnieszka Antioxidants (Basel) Article The aim of this study was to evaluate oxidative stress parameters, specifically the concentration of advanced oxidation protein products (AOPP) and ferric-reducing antioxidant power (FRAP), in the serum of patients with relapsing-remitting multiple sclerosis (RRMS). We also analyzed the relationships between each parameter and selected clinical/laboratory multiple-sclerosis-related parameters. The study group comprised 204 patients with RRMS and 29 healthy, age-matched controls. The concentration of AOPP was significantly higher in the RRMS patients than in controls. ROC analysis showed the ability of AOPP to distinguish between the patients with RRMS and controls (the value of AUC was 94.8%, with a sensitivity of 89.69% and specificity of 89.3%). AOPP and FRAP were significantly higher in male than in female RRMS patients. Correlations were found between AOPP and the laboratory markers of inflammation. AOPP differed in the subgroups of patients treated with particular medications. Our findings indicate an increase in the markers of oxidative stress in the serum of RRMS patients, possibly linked with chronic inflammation. Gender and type of treatment affected the markers of oxidative stress. MDPI 2022-12-07 /pmc/articles/PMC9774652/ /pubmed/36552624 http://dx.doi.org/10.3390/antiox11122416 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bizoń, Anna
Chojdak-Łukasiewicz, Justyna
Kołtuniuk, Aleksandra
Budrewicz, Sławomir
Pokryszko-Dragan, Anna
Piwowar, Agnieszka
Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title_full Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title_fullStr Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title_full_unstemmed Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title_short Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
title_sort evaluation of selected oxidant/antioxidant parameters in patients with relapsing-remitting multiple sclerosis undergoing disease-modifying therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774652/
https://www.ncbi.nlm.nih.gov/pubmed/36552624
http://dx.doi.org/10.3390/antiox11122416
work_keys_str_mv AT bizonanna evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies
AT chojdakłukasiewiczjustyna evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies
AT kołtuniukaleksandra evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies
AT budrewiczsławomir evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies
AT pokryszkodragananna evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies
AT piwowaragnieszka evaluationofselectedoxidantantioxidantparametersinpatientswithrelapsingremittingmultiplesclerosisundergoingdiseasemodifyingtherapies